Is temporal muscle thickness a survival predictor in newly diagnosed glioblastoma multiforme?

Abstract

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. In this study, we aimed to show the relationship between temporal muscle thickness (TMT) measurement and survival in newly diagnosed patients with GBM. Forty-seven patients with newly diagnosed GBM were evaluated, retrospectively. TMT at diagnosis of GBM before any surgical procedure was measured on the contrast-enhanced axial longitudinal relaxation time (T1)-weighted magnetic resonance images. Overall survival (OS) was analyzed by the Kaplan-Meier method and log-rank test was used to determine the differences between the groups. The median TMT was used to determine the cutoff point. The median TMT was 4.7mm (range, 2.8-6.6) in females and 5.4mm (range, 2.9-8.1) in males. Median survival for TMT<4.9mm was 12.9±3.5 (95% CI, 6.0-19.8) months, and 39.4±11.9 (95% CI, 16.0-62.8) months for TMT ≥4.9 (P=.023). In the multivariate Cox regression model, the TMT group (Hazard ratio [HR]=2.07, 95% CI, 0.92-4.61, P=.032) and age group (HR=2.18, 95% CI, 1.01-4.67, P=.014) showed statistically significant difference. TMT is not an independent predictor of response but a predictor of sarcopenia and survival in newly diagnosed GBM. TMT measurement is an easy and practical method. Survival prediction will provide useful information in GBM patients having poor prognosis.